Welcome to Markets Desk, here's what's moving the needle right now.
Prime Medicine got a significant lift today after the FDA cleared its PM six-four-seven therapy for clinical trials, targeting Alpha-one Antitrypsin Deficiency, a rare liver disease. The IND clearance advances the company's prime editing platform into human testing for the first time, and shares of PRME responded accordingly to the upside.
Shifting to macro, Goldman Sachs is making the case that rising U.S. bond yields represent a clear and present danger to domestic equities, and that investors quietly rotating into Japanese markets may already be ahead of the trade. Japan has outperformed on an AI-driven earnings story that hasn't fully registered with American allocators yet, and Goldman's hedge fund desk is flagging it as the credible alternative.
And on the labor market front, a new Monster survey finds that sixty-five percent of workers actively considering a job change are now factoring oil prices directly into their decisions, a consequence of sustained U.S.-Iran military engagement that began seven months ago. Higher gas costs are reshaping compensation expectations in ways that traditional wage data hasn't fully captured, adding a new wrinkle for the Fed as it reads the employment picture.
That's the tape. Markets Desk, signing off the floor.
